Genocea Biosciences (NASDAQ:GNCA) is on a mission to make better cancer immunotherapies for patients, beginning with better target discovery.
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
JMP starts iBio at market outperform; PT $1.50
JMP Securities initiated coverage of iBio (NYSE American:IBIO) with a “market outperform” rating and price target of $1.50. The stock closed at 85 cents, up 19 cents, or 29%, on Nov. 29. iBio is a technology-enabled...
BTIG starts Freeline Therapeutics at buy; PT $10
BTIG launched coverage of Freeline Therapeutics (NASDAQ:FRLN) with a “buy” rating and price target of $10. The stock closed at $2.37 on Nov. 26. Freeline has built a next-generation gene therapy platform based on a...
Omicron variant underscores need for new COVID vaccine candidates like IBIO-202
iBio (NYSE American:IBIO) updated its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron variant of SARS-CoV-2. According to the WHO, the Omicron variant has at least 30 mutations in...
Maxim starts Acurx Pharma at buy; PT $12
Maxim Group initiated coverage of Acurx Pharmaceuticals (NASDAQ:ACXP) with a “buy” rating and $12 price target. The stock closed at $4.89 on Nov. 26. Acurx is developing ibezapolstat, a member of an emerging new class...
BTIG starts MDx Health at buy; PT $15
BTIG launched coverage of MDx Health (NASDAQ:MDXH) with a “buy” rating and price target of $15. The stock closed at $9.04 on Nov. 26. MDx Health is a precision diagnostics company that offers a portfolio of...
Tetra Bio-Pharma posts positive initial data from ongoing Phase 2 trials of QIXLEEF
Tetra Bio-Pharma (TSX:TBP; OTCQB:TBPMF; FRA:JAM1) reported positive initial clinical data from its ongoing Phase 2 REBORN 1 and PLENITUDE trials of QIXLEEF for cancer pain. QIXLEEF is a botanical inhaled investigational...
POINT Biopharma licenses Lu-177 production technology from Belgian Nuclear Research Center
POINT Biopharma Global (NASDAQ:PNT) entered into a technology license agreement with the Belgian Nuclear Research Center (SCK CEN) for Lu-177 purification technology to accelerate POINT’s in-house no-carrier-added...
Cantor starts Fire & Flower at OW; PT $1.30 (Canadian)
Cantor Fitzgerald launched coverage of Fire & Flower Holdings (TSX:FAF) with an “overweight” rating and price target of $1.30 (Canadian). The stock closed at 67 cents on Nov. 23. “Canada’s cannabis retailers...
Raymond James ups Opsens to strong buy; PT $6 (Canadian)
Raymond James upgraded Opsens (TSX:OPS) to “strong buy” from “outperform” with a price target of $6 (Canadian) after the company said its TAVR trial was “very successful.” The stock was quoted at $2.99, down 40 cents...
Analysts start AURA Biosciences at OP, buy
Analysts for SVB Leerink and BTIG initiated coverage of AURA Biosciences (NASDAQ:AURA) with “outperform” and “buy” ratings and price targets of $40 and $38, respectively. The stock closed at $19.82 on Nov. 22. AURA is a...
SVB Leerink starts Airsculpt at OP; PT $26
SVB Leerink launched coverage of Airsculpt Technologies (NASDAQ:AIRS) with an “outperform” rating and price target of $26. The stock closed at $13.61 on Nov. 22. Airsculpt has created an innovative luxury consumer brand...
Analysts start Sonendo at buy, OW
Analyst for Stifel and Piper Sandler initiated coverage of Sonendo (NYSE:SONX) with “buy” and “overweight” ratings and prices targets of $16 and $17, respectively. The stock closed at $10.55 on Nov. 22. Sonendo is a...
Just a few of the companies we’ve highlighted along the way
